Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00396110 |
In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l. This was done in a large observational study (TARGET) representing daily practice. Primary end points analysis was the percentage of patients reaching the target of LDL-C < 3.2 mmol/l. Secondary outcomes were the changes of LDL-C, HDL-C, TC, Triglycerides (TG) and TC/HDL-C-ratio from baseline.
Study Type: | Observational |
Study Design: | Natural History, Longitudinal, Defined Population, Prospective Study |
Official Title: | Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET) |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 25V06, TARGET |
Study First Received: | November 3, 2006 |
Last Updated: | November 3, 2006 |
ClinicalTrials.gov Identifier: | NCT00396110 History of Changes |
Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
cholesterol coronary heart disease rosuvastatin LDL-C goal hypercholesterolemia |
Antimetabolites Arterial Occlusive Diseases Heart Diseases Hyperlipidemias Metabolic Diseases Antilipemic Agents Myocardial Ischemia Vascular Diseases Anticholesteremic Agents Ischemia |
Arteriosclerosis Hydroxymethylglutaryl-CoA Reductase Inhibitors Coronary Disease Rosuvastatin Metabolic Disorder Hypercholesterolemia Coronary Artery Disease Dyslipidemias Lipid Metabolism Disorders |
Antimetabolites Arterial Occlusive Diseases Heart Diseases Hyperlipidemias Metabolic Diseases Molecular Mechanisms of Pharmacological Action Antilipemic Agents Myocardial Ischemia Vascular Diseases Enzyme Inhibitors Anticholesteremic Agents |
Arteriosclerosis Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions Coronary Disease Rosuvastatin Therapeutic Uses Cardiovascular Diseases Hypercholesterolemia Coronary Artery Disease Dyslipidemias Lipid Metabolism Disorders |